Committee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs, Institute of Medicine. "Appendix F: Committee Biosketches." Ethical and Scientific Issues in Studying the Safety of Approved Drugs. Washington, DC: The National Academies Press, 2012.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Ethical and Scientific Issues in Studying the Safety of Approved Drugs
research and vice president of US Medical. She built and led a multinational health economic and outcomes research function, developing and implementing processes to provide clinical and comparative-effectiveness research and generate data needed to support pricing, reimbursement, formulary coverage, and acceptance. She has been involved in comparative-effectiveness research policy, previously serving as a member of the National Advisory Council for the Agency for Healthcare Research and Quality and the Steering Committee for the Centers for Research and Education on Therapeutics. She played a leadership role in the integration of medical–regulatory and clinical research functions during several mergers. She created a US field-based medical team that supported clinical research and communication with medical opinion leaders. As vice present of US Medical, she had responsibility for marketed-product clinical and outcomes research, medical information, public-health and academic partnerships, and regulatory promotional review. Dr. Egbuonu-Davis earned a B.S. in biology from the Massachusetts Institute of Technology, an M.B.A. in health care management from Wharton, and an M.D. and M.P.H. from Johns Hopkins and is a fellow of the American Academy of Pediatrics.
Miguel A. Hernán, M.D., Sc.M., Dr.P.H., is professor of epidemiology at Harvard School of Public Health and an affiliated faculty member of the Harvard–Massachusetts Institute of Technology Division of Health Sciences and Technology. He is an editor of Epidemiology and a Fellow of the American Association for the Advancement of Science. He writes and teaches on methods of causal inference, including comparative effectiveness of policy and clinical interventions. His current research interests include the optimal use of antiretroviral therapy for HIV disease, clinical strategies for the reduction of mortality in people who have kidney failure, and the effects of lifestyle and pharmacologic interventions in reducing the incidence of cardiovascular disease.
Grace M. Lee, M.D., M.P.H., is an associate professor of population medicine and pediatrics at the Harvard Pilgrim Health Care Institute, Harvard Medical School, and Children’s Hospital Boston. She is also an assistant professor of pediatrics in the Division of Infectious Diseases at Children’s Hospital Boston. Dr. Lee’s research focuses on vaccine economics, vaccine safety, and infectious-diseases epidemiology. She recently completed a study funded by the Centers for Disease Control and Prevention (CDC) on emerging gaps in vaccine financing for underinsured children in the United States. She is working on a study funded by the Agency for Healthcare Research and Quality (AHRQ) to determine the potential effects and cost-effectiveness of using a group A streptococcal vaccine and a CDC-funded study of influenza-vaccine safety. Dr. Lee joined the faculty of Harvard Medical School, Harvard Pilgrim Health Care, and Children’s Hospital Boston in 2003 after completing an AHRQ postdoctoral fellowship. She received her M.D. from the University of Pennsylvania School of Medicine and her M.P.H.